TrialBlood2022

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.

Daniel J DeAngelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.